Bone and Cartilage regeneration with cells and tissue engineering products - Dr. Enric Cáceres - B-Debate 17/02/2015
•Transferir como PPT, PDF•
5 gostaram•6,334 visualizações
Bone and Cartilage regeneration with cells and tissue engineering products - Dr. Enric Cáceres - B-Debate 17/02/2015 http://www.bdebate.org/en/forum/advanced-therapies-and-regenerative-medicine-promise-21st-century
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Semelhante a Bone and Cartilage regeneration with cells and tissue engineering products - Dr. Enric Cáceres - B-Debate 17/02/2015
Semelhante a Bone and Cartilage regeneration with cells and tissue engineering products - Dr. Enric Cáceres - B-Debate 17/02/2015 (20)
Último
Último (20)
Bone and Cartilage regeneration with cells and tissue engineering products - Dr. Enric Cáceres - B-Debate 17/02/2015
- 1. Bone and Cartilage regeneration with cells and tissue engineering products Enric Càceres Chair Orthopaedics Universitat Autònoma de Barcelona
- 2. The role of mesenchymal stem cells • Management of large bone defects and cartilage loss continues to be a challenge • Urist 1970 discovers Bone Morphogenetic Protein • Autologous or allogeneic MSCs can be expanded and then may be loaded in the variety of scaffolds
- 3. The role of mesenchymal stem cells MSCs Origin •Bone marrow •Adipose tissue (including fat pad from knee) •Periostium •Synovium •Artery walls
- 4. The role of mesenchymal stem cells
- 5. The role of mesenchymal stem cells
- 6. XCEL-MT-10-02 • Lumbar fusion in degenerative surgery: Autologous iliac graft Gold standard – Local complications – Limited amount of material No union 5-35% (depending condition) • Alternatives: • BMP • Mesenchyme Stem Cells
- 7. XCEL-MT-10-02 PUBMED: Mesenchymal stem cells 26129 Mesenchymal stem cells and bone regeneration 2911 Mesenchymal stem cells and spinal fusion 86 Mesenchymal stem cells and spinal fusion, clinical trial 3
- 8. XCEL-MT-10-02 Biomaterials. 2008 Oct;29(29):3973-82. doi: 10.1016/j.biomaterials.2008.06.026. Epub 2008 Jul 18. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J. Department of Orthopaedics, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China. 41 patients / 95% posterolateral fusion
- 9. XCEL-MT-10-02 Zhonghua Wai Ke Za Zhi. 2008 Apr 1;46(7):493-6. Clinical study of lumbar fusion by hybrid construct of stem cells technique and biodegradable material. [Article in Chinese] Zhang P, Gan YK, Tang J, Hao YQ, Wang Y, Sun YH, Zhu ZA, Dai KR. Department of Orthopaedics, Shanghai Ninth People's Hospital, School of Medicine of Shanghai Jiaotong University, Shanghai 200011, China. Bone marrow mesenchyme stem cells hybridized with beta-tri calcium phosphate 93% fusion Autologous iliac crest bone graft 96% fusion
- 11. 11 Title: "Ex Vivo" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease (XCEL-MT-OSTEO-ALPHA)” Target: Degenerative Spondylolisthesis L4-L5 degrees I-II of Meyerding Product: XCEL-MT-OSTEO-ALPHA Promotion: BST (Banc de Sang i Teixits) Source: Agencia Nacional del medicamento XCEL-MT-10-02
- 12. XCEL-MT-10-02 Design: Phase I/II, prospective, open (blind assessment), randomized, parallel, only one dose and multicentric Centres / IP: Vall d’Hebron, Hosp Germans Trias i Pujol, Hosp del Mar, Hosp St Pau, ICATME-Dexeus Objectives: 1st: To evaluate viability and safety of the product Second: Assess efficacy through image (CT and XR evaluation of fusion status at 6 and 12m) and clinical assessment( VAS, Oswestry, SF-36)
- 13. Experimental study Lead By Mario Aguirre and Roberto Vélez,Hospital Valle Hebron)
- 14. Experimental study Lead By Mario Aguirre and Roberto Vélez,Hospital Valle Hebron)
- 15. Experimental study Focal cryogen insults for inducing osteonecrosis Lead By Mario Aguirre and Roberto Vélez,Hospital Valle Hebron)
- 16. Experimental study Histology of therapeutic model Lead By Mario Aguirre and Roberto Vélez,Hospital Valle Hebron)
- 17. Purpose and hypothesis Purpose Randomized study, compares the spinal fusion obtained after instrumentation and the use of a biologic product (patients MSCs bone marrow fixed in human bone tissue from a donor), with the current procedure that consist in instrumented spinal fusion and the use of each patient’s bone obtained from his/her iliac crest Working hypothesis Proposes that the tissue engineering is valid and useful technique to achieve bone regeneration avoiding iliac crest patient harvesting
- 18. 18 Sample: 62 Patients, age18-85a, bout sex. Group A: Surgical fusion using autologous mesenchymal cells expanded “ex vivo” fixed in allogenic osseous matrix (XCEL-MT- OSTEO-ALPHA)” Group B: Surgical fusion using autologous iliac graft XCEL-MT-10-02
- 21. • Extracción
- 24. • Extracción
- 25. Initial harvest bone marrow Spread Cell Stack Microscopically assessment of the sample celularity and brooding culture Culture andCulture and enlargementenlargement
- 26. Volume Reduction (Spin cycle place the MSCc at the bottom of the pack) CellStacks Strict conditions Cèl-lules mesenquimals, previes a la colonització
- 27. • Extracción
- 30. XR AssessmentXR Assessment independent radiologistindependent radiologist • Molinari score by independent radiologistMolinari score by independent radiologist
- 31. CT AssessmentCT Assessment independent radiologistindependent radiologist • Anterior interbody fusion, facet fusion andAnterior interbody fusion, facet fusion and inter transverse process fusioninter transverse process fusion
- 32. 2014 status of the study2014 status of the study Centre Selected (CI signature) Selection Failure Random Random On going postIQ Concluded Tto A TTo B 1 15 3 8 4 10 3 2 2 9 4 5 5 3 3 3 12 1 5 6 4 2 4 4 4 2 2 2 2 5 5 1 1 1 1 41 4 19 18 22 8
- 33. 007 patient007 patient Radiologist report Posterorolateral multiple graft around rods with continuous bridges more specially in the right side.
- 36. BCN Trials
- 37. Process to applying MSCs for bone repair
- 38. MSCs directly implanted without ex vivo expansion BCN Experience
- 39. Non expanded MSCs • Avoid cost and time • Depend on the number and concentration • <1000 cell per cm3 or< 30.000 cells in total • Small volumes range 2 / 4 ml in aspiration • Centrifuging the aspirate before injection • Lack of strict analysis in many current practice
- 41. Future MCSs in Orthopedics Looks promising as advances in • Tissue engineering • Biomaterial • Cell biology Converge • To play a major role in the repair and regeneration of musculoskeletal disease and injuries